There is just one cause Labiotech exists: to be genuinely helpful to the folks constructing the way forward for biotech. So, from time to time, we return to the one individuals who can reply that: you.
This 12 months, we surveyed our publication subscribers, our most lively and engaged readers. We needed to grasp who you actually are, what you learn and why, the way you interact with our content material, what we might enhance, and whether or not you’ll advocate us to a colleague.
Scientists, traders, enterprise builders, executives, CEOs and extra profiles from throughout Europe, North America, Asia-Pacific, and past, took the time to inform us what you worth, what frustrates you, and the place you need us to go.
That is what you informed us.
Who you’re
Earlier than we speak about your suggestions, it’s value acknowledging who reads Labiotech.
A senior, decision-making viewers
You’re overwhelmingly senior, greater than 80%. Managers, Homeowners, Administrators, Presidents, VPs, CEOs make up most of our readership. Greater than 70% of you’re concerned in buying selections at your office. You’re employed throughout the total spectrum of the trade, in analysis, enterprise improvement, product administration, consulting, operations, and extra, at biotechs, huge pharma, CROs, funding companies, and tutorial establishments, starting from five-person startups to international organizations of over a thousand workers.
Rooted in Europe, learn worldwide
Geographically, Labiotech has a robust dual-core viewers: Europe and North America collectively symbolize the center of our readership, with France, the UK and Germany main on one aspect, and a big US group on the opposite. Past that, you’re based mostly in India, throughout Asia-Pacific, and dozens of different international locations.
You come again. Each week.
The engagement numbers inform their very own story. Practically one in 5 of you devour Labiotech content material day by day, and one other 20% achieve this a number of instances every week. Add the 45% who interact weekly, and the image is placing: greater than 80% of our readership engages with Labiotech a minimum of as soon as every week. You aren’t informal readers. Labiotech has change into a part of your routine.
The codecs you like, and those you haven’t tried but
The publication is your favourite solution to devour Labiotech. 42% of you like it, making it our single strongest asset. Articles on the web site observe carefully. However a number of codecs stay largely undiscovered: webinars, podcasts, companion sources, and LinkedIn posts all present low consciousness quite than lively disinterest. When you haven’t explored them but, now is an effective time to start out!
Belief, earned over time
And the connection runs deep. Practically three-quarters of you price your familiarity with Labiotech at seven out of ten or above, and almost 40% have been studying us for greater than two years. 1 / 4 of you’re new (lower than 1 12 months with us), which tells us the group continues to be rising. On content material high quality, 90% price us seven out of ten or increased. And after we requested how seemingly you’ll be to advocate Labiotech to a colleague, round 80% gave us eight out of ten or above. That’s not a glad viewers. That’s an advocate group.
What drives that notion? You informed us persistently: the standard and reliability of the content material, its depth and analytical rigor, the vary of subjects lined, the European focus, and what a number of of you described as a contemporary spirit.
What you come right here for
Probably the most-cited cause for studying Labiotech was “discovering promising biotech firms, scientific advances, and rising improvements”, not simply the massive names, however the early alerts. That is bolstered by your curiosity in improvement levels: early-stage biotech and preclinical improvement ranked among the many most compelling areas to examine, forward of late-stage and business launches. Additionally rating extremely have been “staying updated on main trade information, traits, and occasion protection”, “monitoring funding rounds and main trade offers”, “accessing in-depth analyses of therapeutic areas or approaches”, and “understanding the strategic strikes of huge pharmaceutical firms.”
On the finish of the day, it comes down to at least one factor: you wish to keep forward. See what’s coming earlier than everybody else, perceive it, and know the place the market goes.
What you wish to examine
On therapeutic areas, the image is obvious. Oncology leads by a big margin, adopted by immunology and autoimmune situations, genetic and genomic illnesses, and neurology and CNS. On the method aspect, the image is simply as clear: cell remedy, protein/biologics, gene remedy and gene modifying, and AI-driven drug discovery dominate.
However the knowledge additionally tells a extra nuanced story. Whereas these areas stand out, your curiosity doesn’t cease there. Throughout the board, curiosity stays sturdy in a remarkably big selection of therapeutic areas and approaches, from cardiovascular to infectious illnesses, from microbiome to peptide therapeutics.
Geography issues too. Europe and North America stay your main areas of curiosity for our protection, however what stands out is how strongly you worth Labiotech’s European perspective particularly. In a media panorama dominated by American voices, you informed us that our deal with the European biotech ecosystem is without doubt one of the issues that makes us completely different. Past Europe and the US, Asia-Pacific types a strong third pillar. Curiosity can also be rising in new frontiers: Latin America and Africa are more and more in your radar.
What you requested us to enhance
Throughout lots of of open-ended responses, a number of subjects emerged persistently:
New codecs you’re asking for
After we requested what you need extra, infographics and visible summaries topped the record, with almost two thirds of you expressing sturdy curiosity. Brief video explainers adopted carefully, alongside digital and in-person occasions and sensible guides and playbooks. The message behind all of that is easy: You wish to devour Labiotech in additional methods, on a commute, in a gathering, or between experiments!
Make it digestible
You’re keen on the depth, however you don’t all the time have the time. Lots of you requested for shorter variations of articles, faster summaries, and extra visible overviews alongside the long-form content material.
Go broader
A number of of you pushed us to increase our horizons: extra regulatory protection, market intelligence briefs, international hub spotlights, and subjects that sit on the edges of biopharma: artificial biology, quantum biology, bioinformatics, and past.
Extra instruments and trackers
You need greater than articles. Throughout lots of of responses, the ask was constant: pipeline trackers, firm and CRO databases, medical trial instruments, downloadable experiences, job boards, richer knowledge, simply to call a couple of.
Repair the expertise
Nice content material deserves an excellent expertise to match. You informed us the place the gaps are: login friction, search performance, cellular readability, and an amazing variety of advertisements. However you additionally painted a transparent image of what you need subsequent : customized newsletters, personalized feeds, and AI-powered instruments that provide help to discover what issues quicker.
What’s coming
The survey gave us a roadmap. Right here is the place we’re heading.
The clearest ask was for content material that’s simpler to soak up: infographics, quick movies, visible summaries alongside the long-form items you already worth. We’re engaged on it and you’ll see a few of these in your social media feeds on LinkedIn already and in a few of our current tales, too.
As regards to occasions, we’re increasing what we already do. Labiotech has run webinars earlier than, however we are going to now be opening them up extra broadly, with each free and premium codecs. Hold your eyes peeled for some particular Labiotech digital occasions in This autumn this 12 months.
We can be feeding your urge for food for brand new and rising science with the launch of a brand new month-to-month collection centered on essentially the most thrilling preclinical property. We’ll even be serving up month-to-month wrap ups of the oncology market for many who wish to preserve their finger on the heart beat of most cancers remedies and applied sciences.
Labiotech was constructed on a conviction that the European biotech ecosystem deserved a voice that’s rigorous, impartial, and genuinely enthusiastic about science. What you informed us, above all, is that you simply belief us. Whether or not you could have been with us for years or have solely simply arrived, meaning all the pieces to our workforce. We don’t take it as a right. We intend to reward you belief with the most effective journalism each single day.
Need to keep linked to Labiotech and get all of the information each week? Subscribe to our publication.
Went to achieve the founders, scientists, and traders who learn Labiotech day-after-day? We’d love to speak.
